LMP744

indenoisoquinoline topoisomerase I inhibitor

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for LMP744, covering 2024-12-10 to 2026-04-24. Get the full timeline:

Most recent: Clinical Trial Update: Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma [Phase 1, Phase 2]